UPDATE 2-AstraZeneca wins U.S. approval for longer use of blood thinner By: Reuters: Company News September 04, 2015 at 04:21 AM EDT * AstraZeneca targeting Brilinta sales of $3.5 bln by 2023 (Adds executive and analyst comments on Brilinta growth) Read More >> Related Stocks: Astrazeneca Plc ADR